Online inquiry

IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12442MR)

This product GTTS-WQ12442MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IFNG gene. The antibody can be applied in Hemophagocytic lymphohistiocytosis (HLH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000619.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3458
UniProt ID P01579
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12442MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9300MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ15833MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ8232MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ12872MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ14186MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ7222MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ4712MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ9500MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J2898A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW